Objectives Most primary central nervous system lymphomas (PCNSLs) and primary vitreoretinal lymphomas (PVRLs) are B-cell lymphomas that produce high levels of interleukin (IL)-10, which is linked to rapid disease progression. The
Introduction
Primary central nervous system lymphomas (PCNSLs) are uncommon extranodal non-Hodgkin's lymphomas (NHLs) that involve only the brain, leptomeninges, spinal cord, and eyes. PCNSL is a rare fatal disease with an incidence of 0.48 in 100,000 persons per year and a 12-month survival of 33 % [1, 2] . The incidence of PCNSL has been increasing over the last 30 years in both immunocompetent and immunodeficient populations [3, 4] . According to the World Health Organization lymphoma classification system, most PCNSLs are diffuse large B-cell lymphomas (DLBCLs) with a heterogeneous population of aggressive malignant B-cells [5, 6] . Primary vitreoretinal lymphoma (PVRL), also known as "primary intraocular lymphoma" (PIOL), is considered a subset of PCNSL that involves the retina, vitreous, and optic nerve head [7] [8] [9] . The incidence of PVRL was 0.46 in 100,000 persons per year in the United States from 2004 to 2007 [10] , and the median overall survival was 22.5 months [7, 11] . The cell of origin for both PCNSL and PVRL is still unknown. However, it is considered to be a B-cell that has exited the germinal center [12, 13] .
PVRLs have been shown to secrete high levels of interleukin-10 (IL-10), and high vitreous IL-10 levels and/or a high vitreous IL-10/IL-6 ratio correspond to a more severe disease course [8, [14] [15] [16] . IL-10 levels are also increased in the cerebrospinal fluid and serum of PCNSL patients compared to patients with other CNS tumors and patients who are free of disease [17] . Higher IL-10 levels correlate with radiographic progression of brain lesions in PCNSL, adverse disease features, and poorer prognosis in DLBCL [17, 18] . This is likely due to the stimulatory effect IL-10 has on B-cells [19, 20] . IL-10 also has a strong immunomodulatory effect, and its ability to inhibit inflammation may be a mechanism tumors use to defy immune surveillance and prevent their destruction [21] .
Single-nucleotide polymorphisms (SNPs) in the IL-10 gene promoter have been described to contribute to risk for NHL [22] [23] [24] [25] . A well-studied SNP in the IL-10 promoter is the IL-10 -1082 G →A allele (IL-10 -1082 ) SNP [26] [27] [28] [29] [30] . There is in vitro and in vivo evidence linking the IL-10 -1082 SNP with IL-10 levels [27, 28, 31, 32] .
Several human malignancies downregulate programmed cell death 4 (PDCD4), a pro-inflammatory tumor suppressor gene that prevents transformation and inhibits cellular proliferation. The PDCD4 protein inhibits protein synthesis by suppressing translation initiation. PDCD4 is downregulated in different tumors, including lung cancer, hepatocellular carcinoma, breast carcinoma, gliomas, and esophageal carcinoma [33, 34] . Mice deficient in PDCD4 develop spontaneous lymphomas and have a short life span [35] . It is via NF-κB that PDCD4 suppresses IL-10 translation [35, 36] .
PCNSLs and PVRLs are extremely rare, and tissue is rarely obtainable for research investigation because of the current modalities of disease treatment. The prevalence of the IL-10 -1082 SNP in PCNSL or PVRL has not been previously reported, and a genotype-phenotype correlation of an IL-10 SNP with IL-10 expression in PCNSL cells or vitreal IL-10 levels in PVRL has not previously been documented. The objectives of the present study, based on the availability of the specimens, were to: (a) compare the IL-10 -1082 SNP in PVRL and PCNSL; (b) determine the correlation of the IL-10 -1082 genotype and the vitreous IL-10/IL-6 ratio in PVRLs; (c) examine for an association between the IL-10 -1082 genotype and IL-10 mRNA levels in PCNSLs; and (d) identify any correlation between PDCD4 and IL-10 mRNA levels in PCNSL.
Materials and methods

Sample collection
The study design was approved by the Institutional Review Boards (IRBs) of the National Eye Institute (NEI) and the University of Liverpool. All participants from the NEI and the University of Liverpool signed informed consent forms. All included patients were HIV negative and had no history of transplantation. The Oregon Health & Science University (OHSU) IRB determined that the research did not involve human subjects, and for this reason, consent was not required or obtained at OHSU. The research adhered to the tenets of the Declaration of Helsinki. The clinic-based cases included 27 patients diagnosed with PVRL at the NEI between 1993 and 2009. The cytology slides of the vitrectomy specimens and vitreous cytokine information from these patients were obtained. Slides from a total of 59 paraffin-embedded brain biopsies containing PCNSL were obtained from Oregon Health & Science University and the University of Liverpool. DNA samples of 98 healthy ageand gender-matched subjects were obtained from the NIH blood bank. Study group populations are summarized in Table 1 .
Vitrectomy and vitreal cytokine measurement
Vitreous specimens from 27 patients subsequently diagnosed with PVRL were obtained through a standard threeport pars plana vitrectomy [37] . The vitrectomy specimens were delivered for cytopathological analysis according to previously described methods [37] . Vitreous supernatant (100 μl per case) was submitted for IL-10 and IL-6 measurement in pg/ml by ELISA (Quantikine; R&D Systems, Abingdon, UK).
Cytology and histology
The vitreous from the 27 PVRL patients was cytocentrifuged (Wescor, Inc. Cytopro 7620, Logan, Utah) at 443 g for 8 min to concentrate cells and cytospun onto glass slides that were subsequently air dried and stained with Giemsa. Brain biopsy tissue with PCNSL was removed surgically, fixed in 10 % neutral buffered formalin, and embedded in paraffin. Neuropathology was determined on 3-or 5-μm-thick sections stained with hematoxylin and eosin (H&E). CD20 positivity was evaluated using routine immunohistochemistry on the PCNSL cases [9] .
Microdissection
Using previously described methods [38] , PVRL cells were microdissected from vitreous cytological slides that were stored at 4°C in a refrigerator for months or years, and PCNSL cells were microdissected from the brain pathological slides that were stored at room temperature for one or several years. Briefly, the buffered formalin-fixed paraffin sections of PCNSL were stained with H&E. Fifty-five of the 59 PCNSL cases were deparaffinized, as four PCNSL cases contained insufficient tissue for further analysis. Lymphoma cells were selected by visualization under a light microscope and collected using a 30-gauge needle as previously described [38] . The PVRL cases collected were all characterized to be B-cell lymphomas based on molecular identification of the IgH gene rearrangement as previously described [39] . For 27 PVRL cases, lymphoma cells on the Giemsa-stained cytological slides were gently lifted and collected with a 30-gauge needle under a light microscope as previously described [40] .
SNP typing
Genomic DNA samples were collected from PVRL cells on the cytospun slides from 27 NEI patients and the PCNSL cells on the pathology slides from 55 cases obtained through OHSU and the University of Liverpool. Ninety-eight blood bank samples from the NIH were also obtained as controls. All samples were amplified using the illustra GenomiPhi V2 DNA Amplification Kit (Amersham Biosciences). Genotyping of rs1800896 was performed (Taqman SNP Genotyping Assays C__1747360_10; Applied Biosystems, Foster City, CA). This procedure was successful for 26 PVRL samples, 35 PCNSL cases, and 96 controls.
RNA isolation and quantitative real-time reverse transcriptase polymerase chain reaction Total RNA from the microdissected cells was isolated using the Paradise TM Sample Quality Assessment Kit (MDS Analytical Technology, Sunnyvale, CA). Universal human RNA was purchased from BD Biosciences (Palo Alto, CA) and used for assay normalization. The cDNA synthesis was performed using SuperScript TM II reverse transcriptase (Invitrogen, Carlsbad, CA). Realtime PCR was performed using a Stratagene Mx3000 Real-Time PCR System and Brilliant SYBR Green QPCR Master Mix (Stratagene, CA). The primers for IL-10 and PDCD4 were synthesized by SA Biosciences (Frederick, MD) and supplied as the quantitative RT-PCR Gene Expression Analysis kit. Following PCR, a thermal melt profile was performed for amplicon identification. To determine the Ct, the threshold level of fluorescence was set manually in the early phase of PCR amplification. The 2-ΔΔCt analysis method was used to determine relative amounts of product using β-actin as an endogenous control. Due to the limited number of microdissected cells, only one common and reliable housekeeping gene, β-actin, was selected. The transcript expression was normalized by the level of β-actin from the same cDNA sample. The average relative expression due to gene manipulation was again normalized to the transcript level of the universal human RNA and presented graphically. Each sample was analyzed twice. Samples without template and samples without PCR mixtures were used as negative controls.
Statistics
Data were analyzed using GraphPad Prism v5. The χ 2 -test was used to detect statistical differences between the genotypic distribution and allelic frequencies of the IL-10 -1082 SNP. The non-parametric Wilcoxon t test was performed to detect statistical differences between vitreous IL-10 levels, vitreous IL-10/IL-6 ratios, and IL-10 mRNA transcript expression. When three or more groups were compared, the ANOVA test was used. The spearmen correlation coefficient (r) was used to evaluate correlation of PDCD4 and IL-10 mRNA expression. Statistical significance was defined as p<0.05.
Results
Demography
The PVRL patient cases from the NEI varied in age from 32 to 81 years, with a mean age of 64 years. All patients were HIV negative and did not have a history of transplantation. The PCNSL patient cases from the Oregon Health & Science University and the University of Liverpool varied in age from 20 to 80 years, with a mean age of 56 years. Demographic information was available for all 26 PVRL patients, 52 PCNSL patients, and 96 control patients (Table 1 ).
Allele and genotype frequencies at IL-10 -1082 in PCNSL and PVRL Genotyping of the IL-10 promoter SNP was successful in 26 of 27 PVRL, 35 of 59 PCNSL patients, and 96 of 98 healthy subjects. There was no significant difference in allele frequencies of the IL-10 -1082 A allele or the IL-10 -1082 G allele in patients with PCNSL or PVRL when compared to controls (Table 2 ). More PVRL patients expressed one copy of the IL-10 -1082 G→A SNP with the GA genotype compared to controls (p00.048), while this was not significant in PCNSL patients (p00.063). There was no statistical difference in genotype frequencies between PCNSL and PVRL. However, there was a statistically significant difference in the frequencies of the three genotypes (AA, AG, GG) in PVRL versus controls (p00.0001) and in PCNSL versus controls (p00.005). Genotypic distributions were in HardyWeinberg equilibrium for blood bank controls, PVRLs, and PCNSLs.
PVRL IL-10 -1082 A allele and higher vitreous IL-10/IL-6 ratios Lymphoma cells from the cytospun slides of 27 PVRL cases were microdissected. A representative image of PVRL cells on a cytospun slide is shown in Fig. 1a . SNP typing was successful in 26 cases. The vitreous IL-10/IL-6 ratio was 6.4±2.6 in patients with IL-10 -1082 GG and 23.5 ± 7.1 in patients with IL-10 -1082 AG or IL-10 -1082 AA (p00.04), as shown in Fig. 2 . Vitreous IL-10 levels (pg/ml) were 724±593 in IL-10 -1082 GG patients and 1,794±603 in IL-10 -1082 AG, and IL-10 -1082 AA patients (p>0.05). PVRLs with at least one IL-10 -1082 A allele have higher vitreous IL-10 levels.
PCNSL IL-10 -1082 A allele and higher IL-10 mRNA levels Of the 59 PCNSL cases (Fig. 1b) , four cases had insufficient tissue for microdissection. Fifty-five cases were microdissected, and total RNA was extracted from microdissected samples and reverse-transcribed to cDNA. RT-PCR for IL-10 Fig. 3 . PCNSLs with at least one IL-10 -1082 A allele have higher IL-10 mRNA levels (Fig. 3b) .
Expression of PDCD4 and IL-10 in PCNSLs
RT-PCR for IL-10 and PDCD4 mRNA was successful in 52 microdissected PCNSL cases. IL-10 and PDCD4 mRNA expression levels were compared in the same cases. When PDCD4 mRNA levels were plotted against IL-10 mRNA levels (Fig. 4) , a weak positive correlation was found: r 2 00.36, with 95 % confidence interval of 0.093 to 0.58 (p00.008).
Discussion
IL-10 gene promoter polymorphisms have been considered risk factors for NHL [22] [23] [24] [25] . There is some evidence suggesting that the IL-10 -1082 A allele is a risk allele in lymphoma patients [26, 41] . One group observed that the frequency of the IL-10 -1082 AA allele was higher in patients with aggressive systemic lymphomas compared to controls [26] . In another study, the frequency of the IL-10 -1082 G allele was higher in patients with DLBCL compared to controls [41] . The IL-10 -1082 A allele has been shown to confer greater overall survival in patients with multiple The mean vitreous IL-10/IL-6 ratios (line) and medians (+) are compared in PVRLs, grouped by genotype at IL-10 -1082 . The difference between the two groups is statistically significant myeloma and chronic lymphocytic leukemia [27] , and the G allele has been associated with a better survival in melanoma patients [42] . Genotype-phenotype studies have measured serum IL-10 levels and IL-10 -1082 SNP expression in vitro after endotoxin stimulation in autoimmune disease and Hodgkin's lymphoma [27-29, 31, 32, 43] . To our knowledge, this is the first study providing a genotype-phenotype correlation for an IL-10 SNP in PCNSL or PVRL.
In this study, we measured the expression of the IL-10 -1082 SNP, IL-10, and PDCD4 in the same PCNSL cases, and therefore were able to make a potential genotype-phenotype correlation. In the PVRL cases, we correlated IL-10 -1082 genotype and vitreous IL-10 levels, which are considered to be a relatively sensitive and specific biomarker of lymphoma cell IL-10 production [14, 44, 45] . Recently, elevation of IL-10 levels in the vitreous has been repeatedly associated with poorer prognosis [16, 46, 47] . A direct relationship cannot be predicted between vitreous IL-10 levels and CSF IL-10 levels, as PVRL cells secrete IL-10 directly into the vitreous, while PCNSL cells may secrete IL-10 remotely from CSF.
However, this is a potential area of investigation in future prospective clinical trials such as the International Extranodal Lymphoma Study Group (IELSG) trail in Europe.
This study demonstrated a similar IL-10 -1082 genotype distribution in PVRLs and PCSNLs, which differed significantly from that observed in healthy controls. Compared to controls, more PVRLs were found to have one copy of the IL-10 -1082 SNP. However, allelic frequency of the IL-10 -1082 A and IL-10 -1082 G alleles was similar in PVRLs, PCNSLs, and controls, supporting evidence of the genetic resemblance of these to nonHodgkin's lymphomas [48] . This finding differs from a previous study that demonstrates an increased prevalence of the IL-10 -1082 G allele in DLBCL patients. In our genotype-phenotype study, we noted that PVRLs with at least one copy of the IL-10 -1082 A allele had a significantly higher vitreous IL-10/IL-6 ratio than PVRLs that were IL-10 -1082 GG. This finding was replicated for PCNSLs, in which we found a significant association between the IL-10 -1082 A allele and higher IL-10 mRNA levels. A dose effect of the IL-10 -1082 A allele seems to be present in both PVRL and PCNSL. Elevated IL-10 levels have been associated with more aggressive disease in PVRL, PCNSL, and NHL [16, 17, [49] [50] [51] . It is possible that the presence of the IL-10 -1082 SNP might predict a worse prognosis for PVRL and PCNSL patients; however, mortality data is necessary to confirm this hypothesis.
DLBCLs may have low PDCD4 levels and higher IL-10 levels. In turn, PDCD4 expression has not been previously reported in PCNSL or PVRL [35, 36, 52] . The tumor suppressor PDCD4 is a pro-inflammatory protein that promotes activation of the transcription factor NF-κB and suppresses interleukin-10 (IL-10). Given that PDCD4 suppresses IL-10, we expected a negative correlation between PDCD4 and IL-10 transcript levels. However, no such relationship was found in 52 PCSNLs. Other factors such as conserved No correlation was detected between PDCD4 and IL-10 mRNA expression levels in primary central nervous system lymphoma (PCNSL) cells non-coding sequences 9 (CNS-9) may regulate IL-10 in PCNSL [53, 54] .
Despite the rarity of these diseases, a large number of PCNSL (n=52) and PVRL (n=26) cases were analyzed. The IL-10 -1082 A allele may not be a direct risk allele for PVRL or PCNSL. However, our study has shown that PVRL patients are more likely to have the IL-10 -1082 SNP than controls and that PVRL and PCNSL patients have an IL-10 -
